[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363989-105":59,"doc-detail-363989-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","exploratory-analysis-of-pten-deficiency-by-immunohistochemistry-from-the-phase-iii-capitello-291-trial","Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial","","Exploratory analysis examines whether immunohistochemistry (IHC) can identify patients with PTEN-deficient tumors in hormone receptor-positive/HER2-negative advanced breast cancer. The study uses tumor samples from the global phase III CAPItello-291 trial to assess PTEN status by IHC and compare it with PTEN alteration status from next-generation sequencing (NGS). Among 367 samples, 70 showed PTEN deficiency by IHC, with high agreement versus NGS. In PTEN-deficient patients, capivasertib plus fulvestrant improves progression-free survival versus placebo.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/exploratory-analysis-of-pten-deficiency-by-immunohistochemistry-from-the-phase-iii-capitello-291-trial/363989/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/exploratory-analysis-of-pten-deficiency-by-immunohistochemistry-from-the-phase-iii-capitello-291-trial/363989.png","ImageObject",300,407,{"name":92,"@type":93},"RuangKosong","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical question does the exploratory analysis address?","Question",{"text":112,"@type":113},"Whether immunohistochemistry can identify PTEN-deficient tumors and provide additional patients who may benefit from capivasertib plus fulvestrant in HR-positive/HER2-negative advanced breast cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were PTEN status and genetic alterations evaluated?",{"text":117,"@type":113},"PTEN status was assessed using immunohistochemistry (IHC), and PTEN alteration status was evaluated using next-generation sequencing (NGS) for PIK3CA/AKT1/PTEN alterations.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key comparison and outcome findings?",{"text":121,"@type":113},"Agreement between PTEN deficiency by IHC and PTEN alteration status by NGS was reported as high overall, with positive, negative, and overall percent agreements. In patients identified as PTEN-deficient by IHC, capivasertib plus fulvestrant improved progression-free survival versus placebo.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363989,1790178092,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962090883219,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Exploratory Analysis of PTEN Deficiency by  \nImmunohistochemistry from the Phase III CAPItello-291 Trial  \nKomal Jhaveri1, Hope S. Rugo2,\\#, Javier Corts3,4,5, Mafalda Oliveira6,7, Sacha J. Howell8,  \nFlorence Dalenc9, Henry L. Gomez10,11, Xichun Hu12, Petr Krivorotko13, Sibylle Loibl14,15, Meena Okera16, Yeon Hee Park17, Joohyuk Sohn18, Masakazu Toi19,\\#, Eriko Tokunaga20, Lyudmila Zhukova21, Agostina Nardone22, Ian Wadsworth23, Celina D’Cruz24,\\#, Tanya Wantenaar25, Dimple Das26,  \nElza [C. de](C. de) Bruin23, and Nicholas C. Turner 27  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: The phosphoinositide 3-kinase (PI3K)/AKT serine/ threonine kinase (AKT) pathway is frequently activated in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, with loss of phosphatase and tensin homolog (PTEN) activity contributing to this activation. Capivasertib is a potent pan-AKT inhibitor, approved in combination with fulvestrant for the treatment of HR-positive/HER2-negative locally advanced/metastatic breast cancer with one or more PIK3CA/AKT1/PTEN tumor alterations. Next-generation sequencing (NGS) is commonly used to identify patients with PIK3CA/AKT1/PTEN tumor alterations. However, the utility of immunohistochemistry (IHC) to identify patients with PTEN-deficient tumors has not been explored in this context.\u003Cbr>Experimental Design: This exploratory analysis was based on tumor samples collected from patients in the global phase III CAPItello-291 study.\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Results: PTEN IHC results were obtained for 367 tumor samples, with 70 (19.1%) identified as PTEN deficient by IHC. A total of 346 (94.3%) samples with a PTEN IHC test result also had NGS test results available for PIK3CA/AKT1/PTEN alteration status. When comparing PTEN deficiency by IHC with PTEN alteration status by NGS, the overall, positive, and negative percent agreements were 87.0%(301/346), 71.9%(23/32), and 88.5%(278/314), respectively. Exploratory analysis in patients with PTEN-deficient tumors by IHC (n ¼ 70) showed improved progression-free survival in the capivasertib plus fulvestrant versus placebo plus fulvestrant treatment arm (median 9.3 vs.\u003Cbr>3.7 months; hazard ratio: 0.52, 95% confidence interval, 0.28– 0.90) .\u003Cbr>Conclusions: These results suggest potential utility for IHC in determining tumor PTEN status in breast cancer and raise the possibility of IHC identifying additional patients who could benefit from treatment with capivasertib and fulvestrant. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nCapivasertib is a potent, selective inhibitor of all three AKTserine/threonine protein kinase (AKT) isoforms (AKT1/2/3) used in the treatment of patients with hormone receptor (HR) -positive/human epidermal growth factor receptor 2 (HER2)-negative  \n1Memorial Sloan Kettering Cancer Center,","cbCaigunOWybafJm","https://ap.wps.com/l/cbCaigunOWybafJm","pdf",1720631,"English","# Introduction\n# Experimental Design\n# Results\n# Conclusions","[{\"question\":\"What clinical question does the exploratory analysis address?\",\"answer\":\"Whether immunohistochemistry can identify PTEN-deficient tumors and provide additional patients who may benefit from capivasertib plus fulvestrant in HR-positive/HER2-negative advanced breast cancer.\"},{\"question\":\"How were PTEN status and genetic alterations evaluated?\",\"answer\":\"PTEN status was assessed using immunohistochemistry (IHC), and PTEN alteration status was evaluated using next-generation sequencing (NGS) for PIK3CA/AKT1/PTEN alterations.\"},{\"question\":\"What were the key comparison and outcome findings?\",\"answer\":\"Agreement between PTEN deficiency by IHC and PTEN alteration status by NGS was reported as high overall, with positive, negative, and overall percent agreements. In patients identified as PTEN-deficient by IHC, capivasertib plus fulvestrant improved progression-free survival versus placebo.\"}]","Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial | PDF",1790154801,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e2e5675ea2ec36bf26ee180e3906064.webp",983,1315,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7cbd09d76edc736421dfd1506971ff61.webp",982,1314,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6a45dcfa3fa1f65784eade09255b6ab.webp",981,1312,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/01539d28f36eb5a14a0b35ac546f99f4.webp",980,1311]